The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of thymosin alpha-1 (TA1) are reviewed. Clinical trials of TA1 for chronic hepatitis B or C ...

TA1 is supplied in single-use vials containing 1.6 mg of lyophilized product. After reconstitution with 1 mL of sterile water, TA1 is to be administered via subcutaneous injection. It should not ...

ASADA is alleging the 34 players and one support person, no longer employed by Essendon, breached the AFL Anti-Doping Code through the use of the banned peptide thymosin beta-4. In December, ASADA ...